The General Pharmaceutical Council has presented "Adhvierte", an action that will focus on the prevention of non-adherence in patients with anxiety or depression who are prone to discontinue treatment for several reasons. Community pharmacists have an essential role in the prevention of therapeutic adherence in these patients, the main objective of this action included in the HazFarma program, which will run from January to June 2022.
